$CADL

Candel Therapeutics, Inc. (CADL): Submission of Matters to a Vote of Security Holders

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001841387 false 0001841387 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23,

Original reporting
Published Jun 24, 2026, 8:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CADL
Neutral
high confidence
Mentioned
$CADL
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CADLNeutralLow
01

Why it matters

This is a confirmation of shareholder voting outcomes (director elections and auditor ratification) rather than a new business development.

02

Market read

Traders typically treat this as low-signal governance housekeeping unless tied to a contested proxy, auditor change, or other material event (none described here).

03

What to watch

The proxy statement details are referenced but not included here; any material changes would need to be checked in the April 29, 2026 definitive proxy.

Relevance 6/10Novelty 2/10Timing: Filed after the June 23, 2026 annual meeting results (June 24, 2026 filing).

Background

The company’s Form 8-K (Item 5.07) reports matters voted on at its June 23, 2026 annual meeting, referencing its April 29, 2026 definitive proxy statement.

Company-level read

Ticker impact

$CADLNeutralHigh confidence
Context

Candel Therapeutics filed an 8-K confirming Annual Meeting results: four Class II directors elected and KPMG ratified for FY2026.

Expected impact

Limited near-term impact; any reaction likely muted unless investors were focused on board/accounting changes.

Evidence & confidence

The filing reports voting tallies and ratification of the auditor, without changes to guidance, trials, financing, or enforcement.

Market effects

No sector read-through; governance/auditor ratification is broadly non-informative for biotech fundamentals.

None indicated.

None indicated.

Counterpoint

If investors were specifically concerned about auditor continuity or board composition, the ratification/election could reduce perceived governance risk, but the filing provides no new risk event.

Key entities

  • Candel Therapeutics, Inc.

    Subject of the SEC 8-K; reported annual meeting voting results and auditor ratification.

  • KPMG LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

$CADLMed

Candel Therapeutics, Inc. (CADL): Results of Operations and Financial Condition

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights • Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 202

$ELVRMed

Elevra Lithium Ltd (ASX:ELV) Corporate Presentation - Outlines Growth Strategy for North American Lithium Platform

Elevra Lithium Ltd (ASX:ELV) outlined its growth strategy for North American Lithium (NAL) in Quebec, targeting 373,000 tonnes of spodumene concentrate annually. FY26 production was 197,967 tonnes, with revenue of US$202 million. The company plans a three-stage expansion, with initial capital expenditure of US$271 million. FY27 production guidance is 198,000 to 210,000 tonnes.

$CVXMedAI 8/10

Chevron (CVX) Doubles Down on Venezuela with a $7 Billion Oil Bet

Chevron (CVX) plans to invest $7 billion in Venezuela over five years to double oil production to 600,000 barrels per day, adding areas in the Orinoco Belt to its joint venture with PDVSA. The move leverages Chevron's existing presence and aims for low-cost growth, despite political and regulatory risks. Venezuela holds the world's largest crude oil reserves but faces infrastructure challenges.